Healthcare firm Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported an increase in adjusted earnings and revenues for the third quarter of
Regeneron Pharmaceuticals Inc.
-(REGN)
XNAS:REGN
REGN Earnings: Regeneron Pharma reports higher Q2 profit and revenue
Healthcare firm Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported an increase in adjusted earnings and revenues for the second quarter of
Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported a decline in adjusted earnings for the first quarter of 2023, despite an increase
Regeneron Pharmaceuticals Inc (REGN) Q1 2023 Earnings Call Transcript
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2023 Earnings Call dated May. 04, 2023 Corporate Participants: Ryan Crowe — Vice President, Investor Relations Leonard S.
Regeneron Pharmaceuticals Inc (REGN) Q4 2022 Earnings Call Transcript
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2022 earnings call dated Feb. 03, 2023 Corporate Participants: Ryan Crowe -- Vice President, Investor Relations Leonard S.
Earnings: Regeneron Pharmaceuticals (REGN) Q4 profit falls as revenues drop 31%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Friday reported a sharp fall in fourth-quarter revenues and adjusted earnings. Total revenues plunged 31% year-over-year
Regeneron Pharmaceuticals Inc (REGN) Q3 2022 Earnings Call Transcript
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Q3 2022 Earnings Call dated Nov. 03, 2022. Corporate Participants: Ryan Crowe -- Vice President, Investor Relations Leonard Schleifer -- President and
Regeneron Pharmaceuticals Inc. (REGN) Q2 2022 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q2 2022 earnings call dated Aug. 03, 2022 Corporate Participants: Ryan Crowe -- Vice President of Investor Relations Leonard
Regeneron Pharmaceuticals Inc. (REGN) Q1 2022 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q1 2022 earnings call dated May. 04, 2022 Corporate Participants: Ryan Crowe -- Vice President of Investor Relations Leonard
Regeneron Pharmaceuticals Inc. (REGN) Q4 2021 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q4 2021 earnings call dated Feb. 04, 2022 Corporate Participants: Mark Hudson -- Director, Investor Relations Leonard S. Schleifer -- Founder,
Regeneron Pharmaceuticals Inc. (REGN) Q1 2021 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q1 2021 earnings call dated May. 06, 2021 Corporate Participants: Justin Holko -- Vice President, Investor Relations Leonard S.
Eylea recovery, COVID antibody cocktail make Regeneron an attractive bet
After last year's mixed performance, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) looks to take advantage of the robust pipeline and the success of
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2020 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Q4 2020 earnings call dated Feb. 05, 2021 Corporate Participants: Justin Holko — Vice President, Investor Relations Leonard S.
Earnings calendar for the week of January 11
Stock markets responded positively to the latest developments in presidential election. On the heels of the Dow Jones Industrial Average achieving a
COVID-19 vaccine: These pharma companies have also made headway
The month of November has been huge for pharmaceutical companies with many submitting positive results from their clinical trials for the development
Regeneron Pharmaceuticals (REGN) Q1 profit jumps 36%, beats estimates
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported a 36% jump in earnings for the first quarter of 2020 helped by higher revenue. The
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2019 Earnings Call Transcript
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2019 Earnings Conference Call Feb. 06, 2020 Corporate participants: Justin Holko -- Investor Relations Leonard S.
Companies that are working on the coronavirus vaccine
The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone.
Three biotech stocks popped up today on Covid-19 treatment related announcements
Biotech companies all over the world have been trying to find the treatment and vaccine for the coronavirus pandemic since January of
Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot
-- Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected. -- Revenues grew 13% to $2.17
Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot
-- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected. --